Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

, Frontiers Editorial Office

doi:10.3389/fonc.2021.707608

RETRACTION article

Front. Oncol., 31 May 2021

Sec. Cancer Molecular Targets and Therapeutics

Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.707608

Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

This article is a retraction of:

RETRACTED: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway
1. Read original article

Frontiers Editorial Office^*

Frontiers Media SA, Lausanne, Switzerland

A Retraction of the Original Research Article
Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway

by Liu J, Zheng Y, Gao Y, Quan Z, Qiao B, Li L, Li T, Duan L, Yang J, Luo C and Wu X (2020). Front. Oncol. 10:75. doi: 10.3389/fonc.2020.00075

Please find the retraction statement below:

Following publication, concerns were raised regarding image manipulation and duplication. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

This retraction was approved by the Chief Editors of Frontiers in Oncology and Chief Executive Editor. The authors agreed to this retraction.

Keywords: KRAS mutation G12C, inhibitor 9, castration-resistant prostate cancer, drug resistance, metastasis

Citation: Frontiers Editorial Office (2021) Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway. Front. Oncol. 11:707608. doi: 10.3389/fonc.2021.707608

Received: 10 May 2021; Accepted: 10 May 2021;
Published: 31 May 2021.

Approved by:

Giuseppe Giaccone, Cornell University, United States

Copyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, ZWRpdG9yaWFsLm9mZmljZUBmcm9udGllcnNpbi5vcmc=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.